Alterity Therapeutics (ASX:ATH) Moat Score: 1/10 (As of Jun. 27, 2026)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
34 GF Score
Price A$0.56
View Full Analysis

What is Alterity Therapeutics Moat Score?

Alterity Therapeutics ASX:ATH -1.75% 34 Moat Score is 1 as of Jun. 27, 2026. GuruFocus rates ASX:ATH with a GF Score™ of 34/100. Among 1,404 Biotechnology companies, Alterity Therapeutics ranks worse than 52.64% on this metric.

Alterity Therapeutics has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Alterity Therapeutics has No Moat: Alterity Therapeutics Ltd has minimal competitive advantages. The company operates in a competitive biotech industry with limited intellectual property, no significant market share, and lacks strong regulatory barriers or customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Alterity Therapeutics might have No Moat - Very weak/transient advantages.

Alterity Therapeutics  (ASX:ATH) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Alterity Therapeutics Moat Score Related Terms

ASX:ATH vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Alterity Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Moat Score falls into.


ASX:ATH
34GF Score
Alterity Therapeutics Ltd ASX:ATH
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Alterity Therapeutics (ASX:ATH) has a Moat Score of 1 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Alterity Therapeutics ranks #739 out of 1404 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Alterity Therapeutics' Moat Score too high?
Alterity Therapeutics' current Moat Score is 1. The Biotechnology industry median Moat Score is 2.00. Alterity Therapeutics' value of 1 is 50% below this industry median. Based on the distribution chart, Alterity Therapeutics ranks #739 out of 1404 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alterity Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #739 out of 1404 companies for Moat Score. This places Alterity Therapeutics in the lower half of its industry. The industry median Moat Score is 2.00. Alterity Therapeutics' value of 1 is 50% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alterity Therapeutics's current Moat Score of 1 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alterity Therapeutics's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Moat Score of 1. The current Moat Score is 1 and 50% below the Biotechnology industry median of 2.00. Alterity Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Moat Score is 1 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for ASX:ATH

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price